Everything below concerns Melanotan II. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-09-16. Numbers and descriptions here follow the published literature rather than marketing material.
Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.
Melanotan-2 appears on the World Anti-Doping Agency prohibited list within the peptide hormone class, and several national regulators treat it as an unapproved prescription substance. Some countries restrict importation or sale for personal use. Because the compound is widely traded as a research chemical, the practical legal picture differs between jurisdictions and shifts over time. Human safety data covering long periods are limited, and whether repeated pigmentation changes carry any lasting risk to melanocytes remains an open question.
Freeze-dried melanotan-2 is normally kept as a desiccated powder at minus twenty degrees Celsius or lower, shielded from light and moisture. Peptides of this size degrade through hydrolysis, oxidation and deamidation, and each pathway accelerates as temperature and water activity rise. Repeated freeze-thaw cycles promote aggregation and loss of material, so aliquoting a stock solution before freezing is standard laboratory practice. Once dissolved, the solution is markedly less stable than the powder. In laboratory work, solutions are generally refrigerated and used within days rather than kept for months.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | Melanotan II; MT-II; N-acetyl-norleucyl-cyclo[Asp-His-D-Phe-Arg-Trp-Lys] amide | Naming follows peptide convention; the numeral distinguishes it from melanotan-1 |
| Molecular formula | C50H69N15O9 | Includes the lactam bridge; no counter-ion assumed |
| Monoisotopic mass | 1023.53 Da | Free base; salts and counter-ions shift the observed value |
| Appearance | White to off-white lyophilised powder | Batch-to-batch colour variation is not itself proof of impurity |
| Typical analytical method | RP-HPLC purity determination with ESI-MS identity confirmation | Retention time alone does not establish sequence identity |
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
Regulatory treatment varies by country. In the United States, melanotan-2 is not approved for any indication, and products marketed for human use fall outside the approved drug framework. Some other jurisdictions have placed it under prescription controls or listed it as a prohibited or restricted substance. Online listings frequently describe the material as a research chemical, a category that does not carry the same manufacturing and labelling requirements as approved medicines.
Solid peptide material is generally stable when kept cold and dry. Common practice is storage at -20 degrees Celsius or lower, with desiccant and protection from light. Repeated freeze-thaw cycles and exposure to moisture are associated with degradation, aggregation, or loss of material. Once dissolved, stability depends on solvent, concentration, and temperature, and solutions are usually treated as short-lived unless stability data support longer periods. Handling notes typically emphasise minimising time at ambient temperature.
Receptor-binding studies classify melanotan II as a non-selective melanocortin agonist. It interacts with MC1R, MC3R, MC4R and MC5R, with reported affinities in the low nanomolar range and no strong subtype preference. Activation of MC1R on dermal melanocytes shifts pigment synthesis toward eumelanin, the dark polymer deposited in melanosomes and transferred to keratinocytes. Because the same peptide engages MC4R in the hypothalamus, it also appears in animal work on food intake and erectile response, which is why it is discussed in both pigment and metabolic research. Which receptor populations dominate after systemic exposure in humans is not fully established.
Published pharmacokinetic information is limited and comes mainly from small studies rather than registrational trials. Plasma half-life is usually described as short, on the order of tens of minutes, followed by rapid tissue distribution and clearance of the intact peptide. Metabolites and low concentrations of parent compound have been reported in urine, a detail relevant to anti-doping and forensic testing. Whether repeated exposure changes receptor sensitivity or clearance over time remains an open question. Values differ noticeably between analytical assays, so published numbers should be read as approximate rather than definitive.
Regulatory treatment of this peptide varies by country. It holds no marketing authorization as a medicine in the United States, the European Union, or most other jurisdictions. Some countries classify products containing it as prescription-only or unlicensed medicines, which restricts lawful supply. Authorities have issued public notices warning that unregulated products may contain undeclared or incorrect ingredients. The molecule also appears on prohibited lists for competitive sport. These measures address supply oversight rather than any approved therapeutic role.
Published research on the compound remains limited. Much of the human data comes from small, early-stage studies rather than large controlled trials, and several questions about effects and variability between individuals remain open. Investigators have examined receptor activity, pigment pathways, and related physiological responses in laboratory and animal models. Findings from those models do not automatically translate to human outcomes. Reviews frequently note the scarcity of rigorous clinical evidence and call for better-characterized study material.
=== MSG === In 1996, the FDA commissioned the Federation of American Society for Experimental Biology (FASEB) to study the effects of MSG, who concluded that MSG is safe for most people. At the time, Ajinomoto also noted the possibility that asthma patients and carriers with symptoms of Chinese restaurant syndrome symptoms may be affected, but ultimately, the safety of this group was also confirmed by subsequent test results in the United States and Australia. In 2020, Ajinomoto along with other activists launched the #RedefineCRS campaign to combat the myth that MSG is harmful to people's health, which highlights both the underlying xenophobic biases against Asian cuisine and scientific evidence that the myth is false. The FDA Food Code 2022 removed MSG from the table of common chemical hazards and associated food and control measures in retail establishments. Low-sodium salt substitutes are considered to be formulations where sodium is reduced – usually by partial or full replacement of NaCl with other chloride and non-chloride salts such as KCl, magnesium chloride, calcium chloride or potassium lactate. Monosodium glutamate (MSG) was also considered a low-sodium salt substitute.
Following receipt of the test results and after further flights by USAAF pilots, the results were so positive that North American began work on converting several aircraft developing into the P-51B/C (Mustang Mk III) model, which became the first long-range fighter to be able to compete with the Luftwaffe's fighters. The definitive version, the P-51D, was powered by the Packard V-1650-7, a license-built version of the two-speed, two-stage-supercharged Merlin 66, introduced the "bubble" canopy, and was armed with six .50 caliber (12.7 mm) AN/M2 Browning machine guns. From late 1943 into 1945, P-51Bs and P-51Cs (supplemented by P-51Ds from mid-1944) were used by the USAAF's Eighth Air Force to escort bombers in raids over Germany, while the RAF's Second Tactical Air Force and the USAAF's Ninth Air Force used the Merlin-powered Mustangs as fighter-bombers, roles in which the Mustang helped ensure Allied air superiority in 1944. The P-51 was also used by Allied air forces in the North African, Mediterranean, Italian, and Pacific theaters. During World War II, Mustang pilots claimed to have destroyed 4,950 enemy aircraft. At the start of the Korean War, the Mustang, by then redesignated F-51, was the main fighter of the United States until jet fighters, including North American's F-86 Sabre, took over this role; the Mustang then became a specialized fighter-bomber. Despite the advent of jet fighters, the Mustang remained in service with some air forces until the early 1980s. After the Korean War, Mustangs became popular civilian warbirds and air racing aircraft.
The two substrates of this enzyme are sequoyitol and oxidised nicotinamide adenine dinucleotide (NAD+). Its products are 2D-5-O-methyl-2,3,5/4,6-pentahydroxycyclohexanone, reduced NADH, and a proton. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-OH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is 5-O-methyl-myo-inositol:NAD+ oxidoreductase. This enzyme is also called D-pinitol dehydrogenase.
is hundreds of milliseconds. This effect is often described using modified Bloch equations that include terms for radiation damping alongside the conventional relaxation terms. The longitudinal relaxation time of radiation damping (
== Cholesteric liquid crystals == Some cholesterol derivatives (among other simple cholesteric lipids) are known to generate the cholesteric liquid crystalline phase. The cholesteric phase is, in fact, a chiral nematic phase, and it changes color when its temperature changes. This makes cholesterol derivatives useful for indicating temperature in liquid-crystal thermometers and in temperature-sensitive paints.
Sources: en.wikipedia.org
During the 2025 legislative session, Moore introduced the Housing for Jobs Act, a bill that would require local governments to automatically approve new housing developments in areas where there are 1.5 jobs for every available housing unit. After the Maryland Association of Counties expressed concerns with the bill, House lawmakers rewrote the bill that requires the state's housing secretary to set a 10-year target for housing production in the state and creates a commission to study the state's housing crisis and develop recommendations on how to address the lack of affordable housing in the state. However, this version of the bill failed to pass the General Assembly. In August 2025, Moore signed an executive order incentivizing the Maryland Department of General Services and the Maryland Department of Transportation to use their available land for housing and accelerate land awards to developers, creates housing production targets for Maryland counties, and instructs all state agencies that use housing-related permits to draft and implement plans to speed up and increase transparency around permit application processing. In January 2026, Moore said he would support three bills to spur construction and increase housing in Maryland, including proposals to encourage mixed-use development projects on state-owned land at train stations and give Maryland developers "early vesting", which would lock in a project's ground rules for five years.
== Career == Aramwit's career started as a Formulator/Research Investigator at Pfizer Pharmaceutical Worldwide in the USA. She then served as the deputy director for International Affairs and Immigrant Workers at the Internal Security Operations Command in Thailand from April 2014 to 2017. Since then, she has been serving as the Acting Vice President on the President and Administrative Board, while concurrently holding the position of Director of Research Projects at Center of Excellence in Bioactive Resources for Innovative Clinical Applications (BRICA) and Dean of the Faculty of Pharmaceutical Sciences at the Department of Pharmacy Practice (PharmCU) at CU. Within these roles, she oversaw collaborations on nutritional supplements with Innobic (Asia) and TISTR, led skincare product development with CU Innovation Hub and UMI Deeptech, and contributed to StemAktiv's research, highlighting its potential in skincare and aging treatment with safe herbal extracts, while also overseeing CU's Faculty of Pharmaceutical Sciences signing an MOU with Mahidol University and another MOU with Degree Plus. In addition, she has been appointed as an adjunct professor in the Faculty of Pharmacy at the Silpakorn University in Thailand and a visiting professor at the Institute of Natural Medicine of the University of Toyama in Japan.
== Applications == Nowadays, synthetic polymers are used in almost all walks of life. Modern society would look very different without them. The spreading of polymer use is connected to their unique properties: low density, low cost, good thermal/electrical insulation properties, high resistance to corrosion, low-energy demanding polymer manufacture and facile processing into final products. For a given application, the properties of a polymer can be tuned or enhanced by combination with other materials, as in composites. Their application allows to save energy (lighter cars and planes, thermally insulated buildings), protect food and drinking water (packaging), save land and lower use of fertilizers (synthetic fibres), preserve other materials (coatings), protect and save lives (hygiene, medical applications). A representative, non-exhaustive list of applications is given below.
Glutathione (GSH, ) is a tripeptide made of the amino acids glutamate, cysteine, and glycine. It is an antioxidant in plants, animals, fungi, and some bacteria and archaea. Glutathione is capable of preventing damage to important cellular components caused by sources such as reactive oxygen species, free radicals, peroxides, lipid peroxides, and heavy metals. It is the most abundant and important low-molecular-mass thiol within most cell types. It is synthesized by attaching cysteine to the carboxyl group of the glutamate side chain with a gamma peptide linkage, and to glycine with a normal peptide bond.
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, containing seven amino acids with a lactam ring and a D-configured phenylalanine residue. It is supplied as a lyophilised powder for laboratory research.
The natural hormone is a linear tridecapeptide that is rapidly degraded in circulation. Melanotan-2 is shortened, cyclised, N-terminally acetylated, and carries a D-amino acid substitution, all of which slow enzymatic breakdown.
No national medicines regulator has approved melanotan-2 for therapeutic or cosmetic use. In several jurisdictions it is treated as an unapproved prescription medicine, and its legal classification differs from country to country.
The lyophilised solid is best kept cold, dry and dark, typically at minus twenty degrees Celsius. Moisture and repeated warming cycles are the main causes of degradation. Solutions prepared from the powder are less stable and are normally used quickly.